Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27376928 | 0.93 | OPRD1 (0.53) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL24760306 | 0.91 | OPRD1 (0.53) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL24774070 | 0.91 | OPRD1 (0.53) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL24760657 | 0.89 | OPRD1 (0.50) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL27439357 | 0.89 | OPRM1 (0.50) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL25964401 | 0.89 | OPRD1 (0.50) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL24760656 | 0.89 | OPRD1 (0.50) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL24765226 | 0.89 | CTSB (0.57) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL27101824 | 0.89 | CTSS (0.53) | OPRM1OPRD1OPRK1CTSBCTSS | |
| SCHEMBL24765338 | 0.89 | ACE (0.54) | OPRM1OPRD1OPRK1CTSBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073610-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | OPRM1 319/4885OPRD1 2192/4885OPRK1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.